An Interventional Study to Assess the Efficacy and Safety of Buprenorphine in Korean Patients With Spinal Disorders

Inclusion Criteria: * 20 years old or above male or female Korean patients * Patients who have spinal disorders related pain * Patients who had been treated with weak opioids and/or NSAIDs before study participation * Patients who have moderate to severe pain intensity * Naïve patients for Buprenorphine (Naïve patient are defined as those who had not been treated with Buprenorphine for 90 days) * Patients who signed a written informed consent form Exclusion Criteria: * Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant. UNLESS they are: * women whose partners have been sterilized by vasectomy or other means * using two birth control methods. The two methods can be a double barrier method or a barrier method plus a hormonal method. Adequate barrier methods of contraception include: diaphragm, condom (by the partner), intrauterine device (copper or hormonal), sponge or spermicide. Hormonal contraceptives include any marketed contraceptive agent that includes an estrogen and/or a progestational agent. * Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive urine pregnancy test * Patients with known hypersensitivity to buprenorphine or to any of the excipients * Patients with severely impaired respiratory function or respiratory depression status * Patients concurrently receiving MAOIs or who have received MAOIs within the previous two weeks * Patients with convulsive disorders, head injury, shock, a reduced level of consciousness of uncertain origin, intracranial lesions or increased intracranial pressure, or in patients with severe hepatic impairment * Patients with biliary tract disorders * Patients known to have, or suspected of having a history of drug abuse * Patients with history of opioid or drug dependence * Patients who are concurrently taking other CNS depressants or muscle relaxants that may cause respiratory depression, hypotension, profound sedation or potentially result in coma. * Patients who are taking Buprenorphine or strong opioid. * Any situation where Buprenorphine is contraindicated * Major surgery within 1 month prior to screening or planned surgery Mainly pain originated other than spinal disorders disease * Non-malignant patients or cancer patients who are receiving any oncology treatment that could affect the measure of pain control * With a disability that may prevent the patient from completing all study requirements and in particular, interfere with 24hrs pain intensity score * Clinically significant impairment of cardiovascular, respiratory and renal function * Patient who needs acute dose titration or whose pain intensity fluctuate significantly in a short period according to investigator's judgment * Having used other investigational drugs at the time of enrollment, or within 30 days of enrollment